KALA BIO, Inc. 8-K

What Happened
KALA BIO, Inc. (KALA) filed an 8-K (Item 5.02) reporting that on February 2, 2026 David Lazar resigned as the Company’s Chief Executive Officer and Chief Financial Officer, while remaining on the board of directors. On the same date the Board appointed current director Avi Minkowitz to serve as the Company’s Chief Executive Officer and Chief Financial Officer, effective February 2, 2026. The filing includes background on Mr. Minkowitz’s business, investment and board experience.

Key Details

• Effective date: February 2, 2026 (resignation and appointment).
• Departing officer: David Lazar resigned as CEO and CFO but remains a director.
• New CEO & CFO: Avi Minkowitz, an existing director, appointed to both roles.
• Minkowitz background highlights: VP at Parkit Enterprise Inc. (Jul 2018–Dec 2020); Analyst at Leonite Capital (Jan 2021–Oct 2024); management consultant since 2023; board member of International Star Inc. (since Oct 2022) and NuRAN Wireless Inc. (since Nov 2025); founder/exits of two companies; holds degrees from York University.
• The filing states there are no family relationships or reportable transactions between Minkowitz and the Company requiring disclosure under Regulation S-K.

Why It Matters
A dual CEO/CFO change is a material leadership event that can affect strategy, financial oversight and investor confidence. The Board chose an internal director (Minkowitz) to assume both roles immediately, which may provide continuity but also concentrates executive responsibility. The 8-K does not disclose any departure or hiring-related compensation or transition arrangements; investors should watch for future filings or disclosures (e.g., Form 4, proxy statements or subsequent 8-Ks) for details on compensation, governance changes or any shifts in strategy.